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The effect of diltiazem vs. saline was studied in a conscious canine model of coronary thrombosis. Dihiazem given as a 0.75 m g / k g  
loading dose intravenously followed by 0.4 m g / k g  intravenously every 4 h for 24 h had no significant effect on thrombus wet weight, 
left ventricular infarct size, frequency of ventricular arrhythmias or ex vivo platelet aggregation. The search for antithrombotic agents 
using in vitro or ex vivo platelet aggregation studies should include concomitant in vivo thrombosis studies using therapeutic dosages 
of the drug in question. 
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1. Introduction 
Recent work in our laboratory indicates that 
diltiazem protects against both regional and global 
myocardial ischemia by inhibition of calcium in- 
gress into ischemic myocardium (Bush et al., 1981). 
We have extended these studies in a conscious 
canine model of coronary thrombosis. While the 
effects of calcium channel blockers on non-cardiac 
and non-smooth muscle cells have been studied 
less extensively than in the cardiac cells, it is 
appealing to consider the potential effect of these 
drugs on the platelet which is centrally involved in 
arterial thrombosis. A variety of direct and indi- 
rect evidence suggests that calcium plays an im- 
portant regulatory role in platelet aggregation and 
release reactions (Detwiler et al., 1978). Thus, 
calcium channel blockers might be expected to 
inhibit platelet aggregation in response to vascular 
injury. 
We hypothesized that diltiazem might have an- 
tithrombotic effects in view of the drug's potential 
for antiplatelet activity in addition to its known 
effect in relieving coronary artery spasm which 
may also contribute to the thrombotic process. 
Our model of coronary thrombosis (Romson et 
al., 1980) is attractive because the animals are 
conscious during thrombus induction and thus the 
intact neural, metabolic and other homeostatic 
processes more closely resemble the clinical state. 
In addition, pharmacologic doses of drugs easily 
tolerated by the open-chest anesthetized animal 
are often poorly tolerated by the conscious animal; 
thus the dosage of a drug given to the conscious 
animal will more closely resemble the clinical 
situation. 
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2. Materials and methods 
2.1. Surgical procedure 
Male mongrel dogs, 12-15 kg, were anesthe- 
tized with intravenous sodium pentobarbital (30 
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m g / k g )  and artificially respirated. Cannulae were 
placed in the left common carotid artery and 
jugular vein and exteriorized through the nape of 
the neck. The heart was suspended in a pericardial 
cradle and the proximal left circumflex coronary 
artery was isolated. A 28 gauge Teflon-coated 
silver wire with 5 m m  of the tip of a 25 gauge 
hypodermic needle secured on the wire's leading 
end was inserted into the circumflex artery and 
affixed to the heart with suture. The pericardium 
and chest were closed in layers. Grass disc 
electrodes were tunneled subcutaneously and ex- 
teriorized along with the intracoronary wire at the 
neck. The dogs were given a single intramuscular 
injection of ampicillin (3 mg/kg) .  A dilute heparin 
solution was placed in the cannulae to maintain 
patency. 
2.2. Electrical stimulation of the left circumflex artery 
and drug treatment 
On the morning following surgery, the animals 
heart rate, blood pressure and electrocardiogram 
were monitored. Only animals free of electro° 
cardiographic evidence of myocardial injury or 
significant arrhythmias were studied further. 
Venous blood was drawn from a foreleg for 
platelet studies (vide infra). Diltiazem 0.75 m g / k g  
or saline was administered as an intravenous load- 
ing dose over l0 min with continuous monitoring 
of the blood pressure and electrocardiogram. 
Venous blood for platelet studies was drawn 60 
min after this loading dose. Subsequently, diltia- 
zero 0.4 m g / k g  or saline was given intravenously 
every 4 h for 5 consecutive doses. Two additional 
animals were given a loading dose of 1.5 m g / k g  of 
diltiazem followed by 0.8 m g / k g  every 4h. An 
individual not directly involved with the experi- 
ment  made up and administered the solutions 
according to a random number table. 
One hour after the loading dose of drug and 
phlebotomy for platelet studies, anodal current 
from a 9V battery was delivered to the intimal 
surface of the circumflex coronary artery via the 
Teflon-coated wire. The current output of 50 /~A 
was adjusted through a 250000~2 potentiometer 
placed in series. The Grass electrodes were con- 
nected to a telemetry transmitter. Electrocardio- 
graphic data were received via telemetry and in 
turn were recorded by a tape recorder pro- 
grammed to record 28 sec of tracing every 15 min. 
The tape was played back later through a Grass 
polygraph for analysis or arrhythmias. 
2.3. Sacrifice 
The 50 #A current to the circumflex artery was 
maintained for 24h, then stopped. Venous blood 
was again drawn for platelet studies. Ventricular 
fibrillation was induced by DC current and the 
heart was removed. The circumflex coronary artery 
in the area of the wire insertion was dissected free 
and the artery was opened lengthwise. The wet 
thrombus was scraped free from t h e i n t i m a  and 
weighed. The heart was then 'breadloafed'  from 
apex to base into 1.0 cm thick slices and incubated 
in 2,3,5-triphenyltetrazolium chloride for 30 min. 
This dye stains normal tissue 'brick-red' by virtue 
of its reaction with myocardial dehydrogenases, 
while unstained dead tissue appears white. The 
non-stained areas were removed and weighed. 
2.4. Ex vivo platelet aggregation 
Platelet aggregation studies were performed 
using previously described spectrophotometric 
methods (Mills and Roberts, 1967) utilizing a Bio- 
Data  platelet aggregometer. Platelet rich plasma 
was prepared by collecting venous blood in 1.0 ml 
of 3.8% sodium citrate to a total volume of 10 ml. 
This was centrifuged at 310 x g for 3 min to obtain 
the platelet rich plasma fraction and then at 2 200 
X g for 10 min to obtain the platelet poor plasma 
fraction. Platelet rich plasma was diluted with 
platelet poor plasma to a platelet count of 
200000 /mm 3 before use in the aggregation assays. 
All platelet samples were assayed within 3 h of the 
time of phlebotomy. Aggregation was initiated un- 
der 3 different conditions using a 50/~1 aliquot of 
aggregating agent added to 450 /~1 of diluted 
platelet rich plasma. Aggregating conditions in- 
clude: collagen (1:80 dilution of Ethicon Collagen 
Dispersion-TD150); 5.0 /~g ADP (Sigma); and 
arachidonic acid (Sigma), 0.65 mM with an addi- 
tional 10/~1 of L-epinephrine (Sigma), 0 .55/IM in 
saline at pH 3. 
2.5. Statistical methods 
All data are expressed as the mean-+ standard 
deviation. Student's t-test for unpaired observa- 
tions and the Wilcoxon rank sum test were used to 
determine statistical significance. A P value of 
< 0.05, treated vs. controls, was considered a sig- 
nificant difference. 
3 .  R e s u l t s  
The mean weight of the saline treated animals 
(n = 5) was 13 -+ 1 kg whereas the mean weight of 
the diltiazem treated animals (n = 5) was 14 + 1 kg 
(P > 0.02). 
The administration of the loading doses of dil- 
tiazem or saline revealed no significant differences 
in heart rate or mean arterial pressure in the 
pre-drug period as compared to the immediate 
post-drug period. A between group comparison 
revealed higher pre- and post-drug heart rates for 
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the saline group (pre, 140 ÷ 19; post, 140 ÷ 18) as 
compared to the diltiazem group (pre, 120-+7; 
post, 121 -+ 7) (P < 0.05). This difference is unex- 
plained. There were no differences between groups 
in mean arterial pressure. 
There was no difference between the diltiazem 
group vs. saline group with respect to thrombus 
wet weight, left ventricular infarct size, infarct as a 
percent of left ventricle or infarct as a percent of 
total heart weight (table 1). A trend for the control 
group to be lower for some of these measures was 
evident. Of interest, two diltiazem treated animals 
had no evidence of infarction despite the presence 
of thrombi. Two animals receiving higher doses of 
diltiazem died before the end of the electrical 
stimulation period. Both animals developed inter- 
mittent marked atrioventricular block and the 
terminal arrhythmias were sinus bradycardia fol- 
lowed by asystole in one animal and ventricular 
fibrillation in the other. Coronary thrombi weighed 
19 mg and 22 mg--approximately the same weights 
as animals treated with diltiazem at a lower dose. 
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Effects of diltiazem vs. saline on coronary thrombosis and left 
ventricular infarction after circumflex stimulation. 
Saline Dihiazem 
( n - 4 )  (n 5) 
Thrombus Wet Weight (mg) 13+7 a 19+ 14 
Infarct (gm) 13+5 15 ~ 17 
Left Ventricle (gm) 49 ~ 7 69~ 18 
Total Heart (gm) 79 + 9 98" 25 
Infarct/Left  Ventricle (%) 26 + 8 23 :~ 23 
Infarct/Total Heart (%) 16 + 7 17~ 17 
,~ X +  S.D. 
Examination of the frequency of premature 
ventricular contractions occurring during the 24 h 
period of stimulation revealed no differences be- 
tween the treated and untreated groups. 
Platelet aggregation studies revealed no dif- 
ferences in the diltiazem group or saline group 
when the one-h and 24-h post-baseline aggregation 
curves were compared to the baseline aggregation 
curve. A representative diltiazem platelet aggrega- 
tion study is displayed in fig. 1. 
4. Discussion 
Diltiazem has no apparent antithrombotic ef- 
fect in this model of coronary thrombosis. This 
result may not be surprising in view of the lack of 
effect of diltiazem on platelet aggregation. It has 
been suggested that platelet aggregation responses 
may not be predictive of in vivo antithrombotic 
effects. While this is especially true in the case o1 
drugs which demonstrate clear-cut in vitro inhibi- 
tion of platelet aggregation without concomitant 
in vivo antithrombotic effects, the opposite situa- 
tion is rarely-observed since most drugs which 
have no in vitro platelet inhibiting properties are 
not studied further with respect to thrombosis. 
An interesting finding in two diltiazem-treated 
animals was the presence of thrombi without in- 
farction. In both cases the thrombi were of suffi- 
cient size to be occlusive. This suggests that diltia- 
zem may have been limiting the ischemic injury as 
has been shown in this laboratory using models of 
global and regional ischemia (Bush et al., 1981). 
Little is known about the effect of diltiazem in 
suppression in ischemic ventricular arrhythmias. 
While no antiarrhythmic effect was observed in 
the current study, it should be noted that this 
model prohibits conclusions because of the experi- 
mental design. Appropriate study of ventricular 
fibrillation thresholds, response to programmed 
electrical stimulation and related studies would 
better answer the question of antiarrhythmic 
potential. 
Diltiazem's inability to inhibit platelet aggrega- 
tion is most likely a reflection of the dosage of 
drug used since in vitro platelet aggregation stud- 
ies of calcium channel blockers indicate an ab- 
sence of antiaggregatory effect at therapeutic con- 
centrations (10 7 M) whereas higher in vitro con- 
centrations (10 5 and I 0 - 6 M )  inhibit platelet 
aggregation (Margolis et al., 1980). 
Caution is advised in extrapolating antithrom- 
botic potential from in vitro platelet aggregation 
studies without the use of concomitant in vivo 
thrombosis studies using therapeutic concentra- 
tions of the drug in question. 
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